An Update on MCO-010 Optogenetics Therapy for Advanced RP

Show Description +

Dr. Mahajan discusses 3-year results of the phase 2b/3 RESTORE trial evalauting MCO-010 (Nanoscope Therapeutics), an optogenetic therapy for retinitis pigmentosa.

Posted: 5/19/2026

Keywords:

retina-meeting-recap

•

MCO-010

•

Optogenetics

•

Retinitis pigmentosa

•

RESTORE

•

Clinical Trials

•

Nanoscope Therapeutics

Up Next

Name: An Update on MCO-010 Optogenetics Therapy for Advanced RP
Uploaded: 2026-05-19T16:25:27+00:00
Description: Dr. Mahajan discusses 3-year results of the phase 2b/3 RESTORE trial evalauting MCO-010 (Nanoscope Therapeutics), an optogenetic therapy for retinitis pigmentosa.

Decreasing Injection Burden for Patients With DME

Katherine E. Talcott, MD

Assessing SHRM With Faricimab Therapy

SriniVas R. Sadda, MD

Using OCT and AI to Evaluate Uveitis

Parisa Emami-Naeini, MD, MPH

Phase 3 Clinical Trial Results for OTX-TKI

Patricio G. Schlottmann, MD

IL-6 Inhibition in Diabetic Macular Edema

Arshad M. Khanani, MD, MA, FASRS, and Roger A. Goldberg, MD

A Potential Noninvasive Therapy for Chronic CSC

Claudio Iovino, MD

Back to All Videos

An Update on MCO-010 Optogenetics Therapy for Advanced RP

Vinit B. Mahajan, MD, PhD

Dr. Mahajan discusses 3-year results of the phase 2b/3 RESTORE trial evalauting MCO-010 (Nanoscope Therapeutics), an optogenetic therapy for retinitis pigmentosa.

Posted: 5/19/2026

Keywords:

retina-meeting-recap

•

MCO-010

•

Optogenetics

•

Retinitis pigmentosa

•

RESTORE

•

Clinical Trials

•

Nanoscope Therapeutics

Please log in to leave a comment.

Meeting Coverage:

Association for Research in Vision & Ophthalmology

An Update on MCO-010 Optogenetics Therapy for Advanced RP

Up Next

An Update on MCO-010 Optogenetics Therapy for Advanced RP

More From ARVO: 2026 Coverage